• Email Us: [email protected]
  • Contact Us: +1 718 874 1545
  • Skip to main content
  • Skip to primary sidebar

Medical Market Report

  • Home
  • All Reports
  • About Us
  • Contact Us

FDA Snubs MDMA Following Flawed Trials And Sexual Abuse Scandal

August 13, 2024 by Deborah Bloomfield

The US Food and Drug Administration (FDA) has rejected an application to allow the use of MDMA for the treatment of post-traumatic stress disorder (PTSD), bringing an end to several years of excitement about the prospect of the party drug becoming medicalized. After analyzing research submitted by drugmaker Lykos Therapeutics, the agency ruled that the data was too patchy, unreliable, and embroiled in scandal to be accepted.

Advertisement

Lykos’ application was based on a pair of Phase III clinical trials, one of which showed that 71 percent of PTSD patients who received MDMA-assisted psychotherapy no longer met the criteria for diagnosis four months after treatment. In a briefing document issued by the FDA in June, the agency acknowledged these findings, explaining that “participants appear to experience rapid, clinically meaningful, durable improvement in their PTSD symptoms.”

However, the document goes on to highlight numerous factors that detract from the reliability of this data. For instance, while the clinical trial was designed as a double-blind study – meaning neither patients nor therapists knew if a participant was assigned MDMA or a placebo – the drug’s very obvious effects make it impossible to hide the truth.

Known as “functional unblinding”, this led to around 90 percent of participants correctly guessing that they had been given MDMA. According to the FDA, “functional unblinding can introduce bias in clinical studies,” thus calling into question the validity of Lykos’ results.

The agency also complained that Lykos had failed to properly track the biological impact of MDMA, and that an assessment of the drug’s safety could therefore not be made. In particular, the compound’s cardiovascular effects may pose a risk to patients with high blood pressure or heart issues, and must therefore be rigorously studied before the drug can be approved for therapeutic use.

Other concerns about Lykos’ decision not to monitor MDMA’s potential for abuse – despite being directed to do so by the FDA – ultimately made up the agency’s mind. Voting 10-1 to reject the drug, an expert panel requested that Lykos conduct another Phase III trial, this time collecting all the necessary data.

Advertisement

Responding to the setback, Lykos CEO Amy Emerson said in a statement that “conducting another Phase III study would take several years,” but insisted that many of the FDA’s queries “can be addressed with existing data, post-approval requirements or through reference to the scientific literature.”

However, in an additional blow, three studies conducted by Lykos-affiliated researchers regarding the use of MDMA for PTSD have now been retracted by the journal Psychopharmacology. The journal’s editors decided to pull the studies in response to a sexual abuse scandal involving unlicensed Lykos therapists and a participant in a Phase II trial back in 2015.

Despite coming clean about the incident and banning those involved in 2019, the Multidisciplinary Association for Psychedelic Studies (MAPS) – of which Lykos is a subsidiary – didn’t disclose this vital information to the journal’s editors when submitting the papers, nor did it remove the data generated during the encounter.

Highlighting these ethical concerns at the FDA’s advisory committee meeting, researcher Nese Devenot from Johns Hopkins University claimed that “in addition to gross violations in Phase II, previously unreported violations include Lykos’s senior leadership having sexual encounters with a vulnerable individual who was then recruited into Phase III.”

Advertisement

“The most significant harms in Lykos’s clinical trials were not caused by MDMA but by the people who were entrusted to supervise its administration,” she said.

The FDA’s decision not to approve the drug means that Australia remains the only country in the world that allows the use of MDMA to treat PTSD. Lykos, however, says it will ask the FDA to reconsider, insisting that its data is robust and untainted by the transgressions of some of its therapists.

Deborah Bloomfield
Deborah Bloomfield

Related posts:

  1. Bolivian president calls for global debt relief for poor countries
  2. Five Seasons Ventures pulls in €180M fund to tackle human health and climate via FoodTech
  3. Humanity’s Journey To A Metal-Rich Asteroid Launches Today. Here’s How To Watch
  4. Ancient DNA Reveals People Caught Leprosy From Adorable Woodland Critters In Medieval England

Source Link: FDA Snubs MDMA Following Flawed Trials And Sexual Abuse Scandal

Filed Under: News

Primary Sidebar

  • North America’s Smallest Turtle Is The Cutest Thing You’ll Find In A Bog
  • “Unambiguous Signal” To Curb Emissions Now: Long-Lost Aerial Photos Reveal Evolution Of Antarctic Ice Shelf Collapse
  • 8 Children Have Been Born With 3 Biological Parents Each After Mitochondrial Transfer
  • First Known Observations Of Matter-Antimatter Asymmetry In Special Particle Decay
  • In 1973, NASA Sent Two Spiders Into Space To See If They Can Spin Webs – And They Learnt A Lot
  • Meet The Many Species Of Freaky Looking “Assassin Spiders” That Only Eat Other Spiders
  • Your Dog’s TV Preferences Might Reveal Their Personality
  • Some Human Gut Bacteria Can Absorb Harmful Toxic “Forever Chemicals” So They Can Be Pooped Out
  • You Could Float Through 10 Countries Before The World’s Most International River Spat You Out
  • Enormous Coronal Hole And Beast-Like Crawling Prominences Dazzle On The Active Sun
  • Dramatic Drone Footage Of Iceland’s Latest Volcanic Eruption Shows An Epic Scene From Hell
  • A Shrimp That Lives In A Tree? Indonesia’s Cyclops Mountains Are Home To Some Seriously Strange Wildlife
  • Is NASA’s Claim That Saturn Could Float On Water Really True?
  • Pangea Proxima: This Is What Planet Earth May Look Like 250 Million Years In The Future
  • The Story Of Dogxim, The Fox-Dog Hybrid That Shouldn’t Have Existed
  • Neanderthal Butchers From Different Caves Had Their Own Specialities
  • On July 20, The US And Canada Will Witness The Little-Known Seven Sisters Eclipse
  • First-Ever Giant Ichthyosaur Soft Tissues Preserved In “Extraordinary Fossil” Dating Back 183 Million Years
  • The Worst Day In History For Humans
  • Could You Survive Being Sucked Into A Tornado?
  • Business
  • Health
  • News
  • Science
  • Technology
  • +1 718 874 1545
  • +91 78878 22626
  • [email protected]
Office Address
Prudour Pvt. Ltd. 420 Lexington Avenue Suite 300 New York City, NY 10170.

Powered by Prudour Network

Copyrights © 2025 · Medical Market Report. All Rights Reserved.

Go to mobile version